The new platinum-based anticancer agent LA-12 induces retinol binding protein 4 in vivo

Proteome Science

Volumn 9, Issue , 2011, Pages

  Bouchal, Pavel ^a,b   Jarkovsky, Jiri ^a   Hrazdilova, Kristyna ^b   Dvorakova, Monika ^a,b   Struharova, Iva ^a,b   Hernychova, Lenka ^b,c   Damborsky, Jiri ^a,d   Sova, Petr ^e   Vojtesek, Borivoj ^b  

^a MASARYK UNIVERSITY   (Czech Republic)

^b MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^c UNIVERSITY OF DEFENCE   (Czech Republic)

^d ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^e Platinum Pharmaceuticals as   (Czech Republic)

Author keywords

(OC 6 43) bis(acetato)(1 adamantylamine)amminedichloro; Adamantylamine; Cisplatin; Platinum (IV) (LA 12)plasma retinol binding protein 4; Proteomics; RBP4

Indexed keywords

AMANTADINE; BIS(ACETATO)(1 ADAMANTYLAMINE)AMMINEDICHLOROPLATINUM; CISPLATIN; LA 12; PLATINUM DERIVATIVE; RETINOL; RETINOL BINDING PROTEIN 4; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; CORRELATION ANALYSIS; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG TARGETING; MALE; NONHUMAN; PROTEIN DETERMINATION; PROTEIN INDUCTION; PROTEOMICS; RAT; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TREATMENT RESPONSE;

RATTUS;

EID: 80055017438     PISSN: None     EISSN: 14775956     Source Type: Journal    
DOI: 10.1186/1477-5956-9-68     Document Type: Article

References (33)

1. Ho YP, Au-Yeung SC, To KK. Platinum-based anticancer agents: innovative design strategies and biological perspectives. Medicinal Research Reviews 2003, 23:633-655. 10.1002/med.10038, 12789689.
2. Kozubik A, Vaculova A, Soucek K, Vondracek J, Turanek J, Hofmanova J. Novel Anticancer Platinum(IV) Complexes with Adamantylamine: Their Efficiency and Innovative Chemotherapy Strategies Modifying Lipid Metabolism. Metal-Based Drugs 2008, 2008:417897. 2291354, 18414587.
3. Choy H, Park C, Yao M. Current status and future prospects for satraplatin, an oral platinum analogue. Clinical Cancer Research 2008, 14:1633-1638. 10.1158/1078-0432.CCR-07-2176, 18347164.
4. Fokkema E, Groen HJ, Bauer J, Uges DR, Weil C, Smith IE. Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer. Journal of Clinical Oncology 1999, 17:3822-3827.
5. Kelland LR. An update on satraplatin: the first orally available platinum anticancer drug. Expert Opinion on Investigational Drugs 2000, 9:1373-1382. 10.1517/13543784.9.6.1373, 11060749.
6. Zak F, Turanek J, Kroutil A, Sova P, Mistr A, Poulova A, Mikolin P, Zak Z, Kasna A, Zaluska D, et al. Platinum(IV) complex with adamantylamine as nonleaving amine group: synthesis, characterization, and in vitro antitumor activity against a panel of cisplatin-resistant cancer cell lines. Journal of Medicinal Chemistry 2004, 47:761-763. 10.1021/jm030858+, 14736257.
7. Turanek J, Kasna A, Zaluska D, Neca J, Kvardova V, Knotigova P, Horvath V, L SI, Kozubik A, Sova P, et al. New platinum(IV) complex with adamantylamine ligand as a promising anti-cancer drug: comparison of in vitro cytotoxic potential towards A2780/cisR cisplatin-resistant cell line within homologous series of platinum(IV) complexes. Anti-Cancer Drugs 2004, 15:537-543. 10.1097/01.cad.0000127147.57796.e5, 15166629.
8. Horvath V, Blanarova O, Svihalkova-Sindlerova L, Soucek K, Hofmanova J, Sova P, Kroutil A, Fedorocko P, Kozubik A. Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells. Gynecologic Oncology 2006, 102:32-40. 10.1016/j.ygyno.2005.11.016, 16364413.
9. Cermanova J, Chladek J, Soval P, Kroutil A, Semerad M, Berankova Z, Siroky P, Surova I. Single-dose pharmacokinetics of a novel oral platinum cytostatic drug ([OC-6-43]-bis[acetato][1-adamantylamine]amminedichloroplatinum [IV]) in pigs. Methods and Findings in Experimental and Clinical Pharmacology 2004, 26:679-685. 10.1358/mf.2004.26.9.872565, 15632953.
10. Sova P, Mistr A, Kroutil A, Zak F, Pouckova P, Zadinova M. Preclinical anti-tumor activity of a new oral platinum(IV) drug LA-12. Anti-Cancer Drugs 2005, 16:653-657. 10.1097/00001813-200507000-00010, 15930894.
11. Sova P, Mistr A, Kroutil A, Zak F, Pouckova P, Zadinova M. Comparative anti-tumor efficacy of two orally administered platinum(IV) drugs in nude mice bearing human tumor xenografts. Anti-Cancer Drugs 2006, 17:201-206. 10.1097/00001813-200602000-00012, 16428939.
12. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22:7265-7279. 10.1038/sj.onc.1206933, 14576837.
13. Horvath V, Soucek K, Svihalkova-Sindlerova L, Vondracek J, Blanarova O, Hofmanova J, Sova P, Kozubik A. Different cell cycle modulation following treatment of human ovarian carcinoma cells with a new platinum(IV) complex vs cisplatin. Investigational New Drugs 2007, 25:435-443. 10.1007/s10637-007-9062-7, 17520175.
14. Roubalova E, Kvardova V, Hrstka R, Borilova S, Michalova E, Dubska L, Muller P, Sova P, Vojtesek B. The effect of cellular environment and p53 status on the mode of action of the platinum derivative LA-12. Investigational New Drugs 2010, 28:445-453. 10.1007/s10637-009-9270-4, 19499188.
15. Hrstka R, Powell DJ, Kvardova V, Roubalova E, Bourougaa K, Candeias MM, Sova P, Zak F, Fahraeus R, Vojtesek B. The novel platinum(IV) complex LA-12 induces p53 and p53/47 responses that differ from the related drug, cisplatin. Anti-Cancer Drugs 2008, 19:369-379. 10.1097/CAD.0b013e3282f7f500, 18454047.
16. Kvardova V, Hrstka R, Walerych D, Muller P, Matoulkova E, Hruskova V, Stelclova D, Sova P, Vojtesek B. The new platinum(IV) derivative LA-12 shows stronger inhibitory effect on Hsp90 function compared to cisplatin. Molecular Cancer 2010, 9:147. 10.1186/1476-4598-9-147, 2893458, 20550649.
17. Sova P, Mistr A, Kroutil A, Semerad M, Chlubnova H, Hruskova V, Chladkova J, Chladek J. A comparative study of pharmacokinetics, urinary excretion and tissue distribution of platinum in rats following a single-dose oral administration of two platinum(IV) complexes LA-12 (OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV) and satraplatin (OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum(IV). Cancer Chemotherapy and Pharmacology 2011, 67:1247-1256. 10.1007/s00280-010-1411-0, 20697713.
18. Pilny R, Bouchal P, Borilova S, Ceskova P, Zaloudik J, Vyzula R, Vojtesek B, Valik D. Surface-enhanced laser desorption ionization/time-of-flight mass spectrometry reveals significant artifacts in serum obtained from clot activator-containing collection devices. Clinical Chemistry 2006, 52:2115-2116. 10.1373/clinchem.2006.073841, 17068172.
19. Tang XH, Gudas LJ. Retinoids, retinoic acid receptors, and cancer. Annual Review of Pathology 2011, 6:345-364. 10.1146/annurev-pathol-011110-130303, 21073338.
20. Brozkova K, Budinska E, Bouchal P, Hernychova L, Knoflickova D, Valik D, Vyzula R, Vojtesek B, Nenutil R. Surface-enhanced laser desorption/ionization time-of-flight proteomic profiling of breast carcinomas identifies clinicopathologically relevant groups of patients similar to previously defined clusters from cDNA expression. Breast Cancer Research 2008, 10:R48. 2481497, 18510725.
21. Moshkovskii SA, Serebryakova MV, Kuteykin-Teplyakov KB, Tikhonova OV, Goufman EI, Zgoda VG, Taranets IN, Makarov OV, Archakov AI. Ovarian cancer marker of 11.7 kDa detected by proteomics is a serum amyloid A1. Proteomics 2005, 5:3790-3797. 10.1002/pmic.200401205, 16121334.
22. Schagger H. Tricine-SDS-PAGE. Nature Protocols 2006, 1:16-22. 10.1038/nprot.2006.4, 17406207.
23. Matsui NM, Smith-Beckerman DM, Epstein LB. Staining of Preparative 2-D Gels. 2-D Proteome Analysis Protocols 1999, 112:307-311. Totowa, New Yersey: Humana Press, L AJ.
24. Havlasova J, Hernychova L, Brychta M, Hubalek M, Lenco J, Larsson P, Lundqvist M, Forsman M, Krocova Z, Stulik J, Macela A. Proteomic analysis of anti-Francisella tularensis LVS antibody response in murine model of tularemia. Proteomics 2005, 5:2090-2103. 10.1002/pmic.200401123, 15892173.
25. Kanai M, Raz A, Goodman DS. Retinol-binding protein: the transport protein for vitamin A in human plasma. Journal of Clinical Investigation 1968, 47:2025-2044. 10.1172/JCI105889, 297364, 5675424.
26. Tsunoda S, Smith E, De Young NJ, Wang X, Tian ZQ, Liu JF, Jamieson GG, Drew PA. Methylation of CLDN6, FBN2, RBP1, RBP4, TFPI2, and TMEFF2 in esophageal squamous cell carcinoma. Oncology Reports 2009, 21:1067-1073.
27. Zovich DC, Orologa A, Okuno M, Kong LW, Talmage DA, Piantedosi R, Goodman DS, Blaner WS. Differentiation-dependent expression of retinoid-binding proteins in BFC-1 beta adipocytes. Journal of Biological Chemistry 1992, 267:13884-13889.
28. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L, Kahn BB. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005, 436:356-362. 10.1038/nature03711, 16034410.
29. Zanotti G, Ottonello S, Berni R, Monaco HL. Crystal-Structure of the Trigonal Form of Human Plasma Retinol-Binding Protein at 2.5-Angstrom Resolution. Journal of Molecular Biology 1993, 230:613-624. 10.1006/jmbi.1993.1173, 8464067.
30. Cross-Reference To Related Source. , http://www.freepatentsonline.com/y2008/0033053.html
31. Hung YC, Huang GS, Lin LW, Hong MY, Se PS. Thea sinensis melanin prevents cisplatin-induced nephrotoxicity in mice. Food and Chemical Toxicology 2007, 45:1123-1130. 10.1016/j.fct.2006.12.017, 17303299.
32. ExPASy. , http://www.expasy.org/cgi-bin/protparam1?P04916@noft@
33. Lorkova L, Pospisilova J, Lacheta J, Leahomschi S, Zivny J, Cibula D, Petrak J. Decreased concentrations of retinol-binding protein 4 in sera of epithelial ovarian cancer patients: A potential biomarker identified by proteomics. Oncology Reports